Depression After Injury: Medications, Prior Authorization Barriers, and the Pharmacy Lien

James Wong — Founder & Pharmacist, LienScripts | February 21, 2026 | 8 min read

Chronic pain patients develop depression at 3 to 4 times the rate of the general population. Learn how SSRIs, SNRIs, bupropion, and mirtazapine are used in PI cases, why insurers delay access, and how the pharmacy record documents psychological damages.

The Chronic Pain–Depression Connection

Chronic pain and depression are not coincidentally linked. They share overlapping neural pathways — the same descending pain inhibitory circuits that modulate pain perception also regulate mood, motivation, and emotional resilience. When a personal injury produces persistent pain, those shared circuits become dysregulated, and depression follows at rates that are three to four times higher than in the general population.

Research published in peer-reviewed literature consistently documents this relationship. A meta-analysis in Pain found that individuals with chronic pain conditions have substantially elevated rates of major depressive disorder, and conversely, that comorbid depression amplifies pain intensity, reduces physical function, and extends recovery timelines.

[!SOURCE] Bair MJ, Robinson RL, Katon W, Kroenke K. "Depression and pain comorbidity: a literature review." Archives of Internal Medicine. 2003;163(20):2433-2445. PMID: 14609780.

For personal injury attorneys, this means that a serious accident producing chronic pain will frequently produce a comorbid depressive disorder — and that the medications prescribed to treat that depression are legitimately part of the injury-related medical expenses. Insurers, predictably, dispute these medications at every turn.

This article covers the major antidepressant classes used in PI cases, the prior authorization barriers that delay treatment, and how the pharmacy record built under a lien documents psychological damages in the demand package.

Why Physicians Prescribe Antidepressants Alongside Pain Medications

The prescription of antidepressants in a personal injury case is not evidence that the pain is "all in the patient's head." Physicians prescribe antidepressants alongside analgesics for well-established clinical reasons:

Independent depression treatment: When a claimant meets DSM-5 criteria for major depressive disorder as a result of the injury's functional consequences — inability to work, loss of recreational activities, disrupted relationships, chronic sleep problems — antidepressant pharmacotherapy is the standard of care.

Pain modulation: Several antidepressants, particularly SNRIs and tricyclics, independently modulate pain pathways through their effects on norepinephrine and serotonin in descending pain inhibitory circuits. A physician prescribing duloxetine for a claimant with both depression and neuropathic pain is treating both conditions simultaneously with a single medication.

Sleep restoration: Antidepressants with sedating profiles (mirtazapine, amitriptyline, trazodone) address the sleep disruption that is nearly universal in chronic pain and depression — a disruption that amplifies both pain perception and depressive symptoms if left untreated.

Reducing opioid requirement: When antidepressants improve the mood and sleep dimensions of the pain experience, some patients achieve adequate pain control with lower opioid doses. This is clinically desirable and reflects sound prescribing judgment, not polypharmacy excess.

[!KEY] A prescription for an antidepressant in a personal injury case is clinical evidence of the injury's psychological impact — not a challenge to the legitimacy of the physical injury claims. Attorneys should frame antidepressant prescriptions as psychological damages evidence, not as something to minimize or explain away.

SSRIs: First-Line for Depression in PI Cases

Selective serotonin reuptake inhibitors are the first-line pharmacological treatment for major depressive disorder and are the most commonly prescribed antidepressants in personal injury cases.

Sertraline (Zoloft) — Among the most widely prescribed antidepressants globally. Sertraline has strong evidence for major depressive disorder, generalized anxiety disorder, and PTSD — all conditions that frequently co-occur after serious personal injury. Dosing is 50–200 mg/day. It is generic and relatively inexpensive when covered by insurance, but insurers still demand prior authorization for the brand-name formulation and occasionally dispute the indication in PI cases.

Escitalopram (Lexapro) — Considered one of the best-tolerated SSRIs due to its high selectivity. Research in Lancet (2009) comparing antidepressant efficacy and tolerability found escitalopram to have favorable outcomes across both dimensions. Dosing is 10–20 mg/day. In PI cases, escitalopram is frequently prescribed when sertraline produces inadequate response or intolerable side effects.

[!SOURCE] Cipriani A, et al. "Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis." Lancet. 2018;391(10128):1357-1366. PMID: 29477251.

SNRIs: Treating Both Depression and Pain

Serotonin-norepinephrine reuptake inhibitors occupy a particularly important role in personal injury pharmacotherapy because of their dual action on both mood and pain.

Duloxetine (Cymbalta) — FDA-approved for major depressive disorder, generalized anxiety disorder, fibromyalgia, diabetic neuropathy, and musculoskeletal pain. In a personal injury case involving both depression and neuropathic or musculoskeletal pain, duloxetine may be the single most strategically important medication in the pharmacy record — it demonstrates that the injury produced a condition severe enough to require an FDA-approved treatment for multiple injury-related diagnoses simultaneously. Typical dosing is 60–120 mg/day.

Venlafaxine (Effexor XR) — An SNRI with FDA approval for major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder. Venlafaxine is particularly useful when anxiety is a prominent comorbidity, which is common after traumatic accidents. Dosing is 75–225 mg/day in extended-release form.

Bupropion: A Distinct Mechanism for Depression and Fatigue

Bupropion (Wellbutrin XL, Aplenzin) — A norepinephrine-dopamine reuptake inhibitor with a pharmacological profile distinct from SSRIs and SNRIs. Bupropion does not affect serotonin, which makes it useful when serotonergic agents have been tried and failed or were poorly tolerated. It is notable for its activating profile — unlike SSRIs that can produce initial sedation, bupropion tends to increase energy and motivation, which addresses the anhedonia and fatigue dimensions of depression common in chronic pain patients.

Bupropion also carries FDA approval for smoking cessation (Zyban), and prescribing physicians in PI cases may address smoking-related health impacts simultaneously. In the demand package, a bupropion prescription documents that the physician was managing a depressive disorder that did not respond adequately to first-line serotonergic agents.

Mirtazapine: Targeting Depression, Sleep, and Appetite Together

Mirtazapine (Remeron) — A noradrenergic and specific serotonergic antidepressant (NaSSA) with a unique receptor profile that produces sedation, appetite stimulation, and antidepressant effects simultaneously. Mirtazapine is particularly valuable in PI cases when the claimant presents with a depressive syndrome characterized by:

• Insomnia or fragmented sleep (common after traumatic injury)
• Appetite loss and weight loss (a DSM-5 criterion for depression)
• Prominent anxiety alongside depressed mood

Dosing is counterintuitively lower for sleep (7.5–15 mg) and higher for antidepressant effect (30–45 mg), reflecting different receptor binding profiles at different doses. In the pharmacy record, mirtazapine at bedtime alongside a daytime SSRI or SNRI documents a physician managing a complex depressive presentation that required multimodal pharmacotherapy.

Prior Authorization Barriers in PI Cases

Antidepressant prior authorization in personal injury cases creates delays that compound the psychological harm:

Brand-name restrictions: Insurers require documented failure with generic alternatives before approving branded formulations (Effexor XR, Pristiq, Cymbalta). This step therapy requirement can add 4–8 weeks to treatment initiation while the insurer waits for documented generic trials.

Indication specificity: When a physician prescribes duloxetine for musculoskeletal pain in a patient who also has depression, the insurer may approve the pain indication but dispute coverage for the depression indication — or vice versa — creating administrative complexity that delays the prescription.

Formulary restrictions: Many health plans have preferred antidepressant tiers, and non-preferred agents require prior authorization regardless of the clinical rationale. An insurer that prefers sertraline will resist escitalopram without step therapy documentation.

The PI coverage gap: In most PI cases, the claimant's health insurance — if they have it — does not cover injury-related treatment because liability is disputed. Medpay coverage is finite. Without a pharmacy lien, the claimant may simply go without antidepressant treatment for months while the administrative disputes play out.

[!KEY] Untreated depression in a personal injury claimant is not just a health problem — it is a damages amplifier. Depression impairs pain coping, extends recovery, reduces treatment compliance, and increases the likelihood of opioid misuse. A pharmacy lien that ensures uninterrupted antidepressant access from day one produces better clinical outcomes and stronger damages documentation simultaneously.

How the Pharmacy Lien Covers the Full Psychiatric Medication Protocol

LienScripts dispenses the full antidepressant regimen under a lien arrangement: SSRIs, SNRIs, bupropion, mirtazapine, and any adjunctive agents prescribed by the treating physician. Repayment is deferred to case settlement.

There are no prior authorization barriers, no formulary tier restrictions, and no step therapy requirements. The prescribing physician writes the prescription; the patient receives the medication.

For complex presentations where multiple medications are prescribed simultaneously — for example, duloxetine for depression and neuropathic pain plus mirtazapine at bedtime for sleep and appetite — the pharmacy record captures the full complexity of the treatment protocol with every dispense timestamped and diagnosis-coded.

Using the Antidepressant Record to Document Psychological Damages

Attorneys building the demand package should treat the antidepressant pharmacy record as psychological damages evidence:

Diagnosis documentation: Each prescription carries an ICD-10 diagnosis code. F32.x (major depressive episode) or F33.x (major depressive disorder, recurrent) appearing on monthly antidepressant refills creates a consistent, third-party documented diagnostic record.

Treatment duration as severity indicator: A claimant who has been filling antidepressants continuously for 24 months demonstrates a persistent depressive disorder — not an acute, transient response to injury. The duration of pharmacotherapy is evidence of severity.

Medication complexity as functional impairment indicator: When the pharmacy record shows an SNRI for depression and pain, a sedating agent for sleep, and multiple dose adjustments over time, it documents a physician managing a complex, treatment-resistant syndrome — far more persuasive than a claimant's testimony alone about feeling sad.

Comorbidity mapping: When antidepressants appear alongside pain medications, muscle relaxants, and TBI medications in the same pharmacy record, the combination paints a comprehensive picture of the injury's total functional impact — physical and psychological — on the claimant's daily life.

Economic damages bridge: Depression impairs work capacity. When vocational experts opine on reduced earning capacity, the antidepressant medication record supports their opinion by documenting a treated psychiatric condition that the claimant's own physician considered serious enough to require ongoing pharmacotherapy.

Special Considerations: When Antidepressants Are Changed

Medication changes — switching from sertraline to venlafaxine, or adding mirtazapine after duloxetine alone proved insufficient — are clinically significant events that the pharmacy record captures in real time. For the demand package, medication switches document:

• That the initial treatment was inadequate, suggesting a more severe or treatment-resistant depression
• That the treating physician was actively managing a real condition (not simply writing a prescription and not following up)
• That the psychological injury evolved and required clinical reassessment over time

These details strengthen the narrative that the depression is genuine, ongoing, and causally connected to the accident.

Related Resources

• PTSD Medications After Personal Injury
• Spravato (Esketamine) for Depression After Personal Injury
• Chronic Fatigue After TBI: Medications and the Pharmacy Lien
• Fibromyalgia After an Accident: Medications and Causation
• Gabapentin vs. Pregabalin in Personal Injury Cases
• What Is a Pharmacy Lien?